Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

BACKGROUND: We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a phase 3 remdesivir trial and a retrospective cohort of patients with severe COVID-19 treated with standard of care. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Olender, Susan A, Perez, Katherine K, Go, Alan S, Balani, Bindu, Price-Haywood, Eboni G, Shah, Nirav S, Wang, Su, Walunas, Theresa L, Swaminathan, Shobha, Slim, Jihad, Chin, BumSik, De Wit, Stéphane, Ali, Shamim M, Soriano Viladomiu, Alex, Robinson, Philip, Gottlieb, Robert L, Tsang, Tak Yin Owen, Lee, I-Heng, Hu, Hao, Haubrich, Richard H, Chokkalingam, Anand P, Lin, Lanjia, Zhong, Lijie, Bekele, B Nebiyou, Mera-Giler, Robertino, Phulpin, Chloé, Edgar, Holly, Gallant, Joel, Diaz-Cuervo, Helena, Smith, Lindsey E, Osinusi, Anu O, Brainard, Diana M, Bernardino, Jose I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454434/
https://www.ncbi.nlm.nih.gov/pubmed/32706859
http://dx.doi.org/10.1093/cid/ciaa1041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454434/
https://www.ncbi.nlm.nih.gov/pubmed/32706859
http://dx.doi.org/10.1093/cid/ciaa1041

Ejemplares similares